Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.37 |
| ▸ | ROR1 | Q01973 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 10/20 | 0.36 |
| ▸ | MAOA | P21397 | 3/20 | 0.36 |
| ▸ | THRA | P10827 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5854730 | 0.93 | CYP19A1 (0.38) | CYP19A1ROR1KCNH2TRPV1MAOB | |
| SCHEMBL5856692 | 0.91 | MAOB (0.52) | MAOBMAOAALDH1A1HPGDNPC1 | |
| SCHEMBL5855991 | 0.83 | CYP19A1 (0.47) | CYP19A1KCNH2TRPV1MAOBALDH1A1 | |
| SCHEMBL5854453 | 0.82 | CYP19A1 (0.36) | CYP19A1ROR1KCNH2TRPV1MAOB | |
| SCHEMBL5855367 | 0.77 | MAOB (0.44) | CYP19A1MAOBALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL5854449 | 0.76 | KDM4E (0.36) | MAOBMAOAALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL27560358 | 0.72 | PTPN1 (0.32) | ROR1MAOBMAOAALDH1A1HPGD | |
| SCHEMBL27538820 | 0.72 | PTPN1 (0.36) | ROR1MAOBMAOAALOX15 | |
| SCHEMBL226085 | 0.72 | KCNH2 (0.65) | CYP19A1ROR1KCNH2TRPV1THRA | |
| SCHEMBL5855134 | 0.72 | KDM4E (0.46) | CYP19A1MAOBMAOAALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074819-B2 | Benzopyran or thiobenzopyran derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-07-11 | — | — | US | disclosed |
| US-20040102479-A1 | Novel benzopyran or thiobenzopyran derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2004-05-27 | — | — | US | disclosed |
| US-6645951-B1 | Antiestrogens for treating breast cancer | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-11-11 | — | — | US | disclosed |
| US-6555571-B2 | Hormone inhibitor; sexual disorders | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-04-29 | — | — | US | disclosed |
| US-20030013756-A1 | 3-methyl -chromane or thiochromane derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-01-16 | — | — | US | disclosed |
| EP-0944613-B1 | BENZOPYRAN DERIVATIVES | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2002-10-09 | — | — | EP | disclosed |
| EP-1087959-A1 | NOVEL BENZOPYRAN OR THIOBENZOPYRAN DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-04-04 | — | — | EP | disclosed |
| US-6153768-A | RECEPTOR BLOCKING ANTIESTROGENS HAVING REDUCED SIDE EFFECTS | C & C RESEARCH LABORATORIES (KR) | 2000-11-28 | — | — | US | disclosed |
| WO-1999065893-A1 | NOVEL BENZOPYRAN OR THIOBENZOPYRAN DERIVATIVES | C & C RESEARCH LABORATORIES (KR) | 1999-12-23 | — | — | WO | disclosed |
| EP-0944613-A1 | NOVEL BENZOPYRAN DERIVATIVES | C & C Research Laboratories (KR) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998025916-A1 | NOVEL BENZOPYRAN DERIVATIVES | C & C RESEARCH LABORATORIES (KR) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102479-A1 | Novel benzopyran or thiobenzopyran derivatives | NR5A1, SHBG, ESR2 | CYP19A1 4/4885ROR1 127/4885KCNH2 3734/4885 |
| US-20030013756-A1 | 3-methyl -chromane or thiochromane derivatives | ESR2, GPER1, NR5A1 | CYP19A1 7/4885ROR1 149/4885KCNH2 1998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.